The global thyroid gland disorders treatment market size is anticipated to reach US$ 2,710.9 Mn by 2026 at a CAGR of 3.7% from 2019 to 2026.
The report analyzes and forecasts the thyroid gland disorders treatment market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of thyroid gland disorders treatment, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major thyroid gland disorders treatment companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of thyroid gland disorders treatment upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of thyroid gland disorders treatment and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global thyroid gland disorders treatment market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the thyroid gland disorders treatment market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of thyroid gland disorders treatment market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the global thyroid gland disorders treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the Thyroid Gland Disorders Treatment Market are Merck KGaA, Pfizer, Inc., Takeda Pharmaceutical Company Limited, ALLERGAN, Sanofi S.A., AbbVie Inc., Lannett Company, Inc., Aspen, Novartis AG, Mylan N.V., and Others.
Report Segmentation:
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Thyroid Gland Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
3.2. Global Thyroid Gland Disorders Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Thyroid Gland Disorders Treatment Market: Product Overview
4.2. Global Thyroid Gland Disorders Treatment Market: Key Industry Developments
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increasing incidence of thyroid gland disorders
5.2.2. Rise in the number of obese, diabetic, and cardiovascular patients, leading to increased risk of thyroid disorders
5.2.3. Growing number of disease awareness programs in developing regions
5.2.4. Focus on spreading awareness about disorders as well as promotional campaigns
5.2.5. Development of effective combination thyroid disorders drug therapies
5.3. Restraints
5.3.1. Rising customer preference for alternative treatments
5.3.2. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
5.4. Opportunities
5.4.1. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
5.4.2. Increase in research and development activities
5.5. Global Thyroid Gland Disorders (Hypothyroidism and Hyperthyroidism) Epidemiology
5.6. Global Thyroid Gland Disorders Treatment Market Revenue Forecast
5.7. Global Thyroid Gland Disorders Treatment Market Outlook
6. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders
6.1. Introduction
6.2. Key Insights
6.3. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders
6.3.1. Hypothyroidism
6.3.1.1. Levothyroxine
6.3.1.2. Liothyronine
6.3.2. Hyperthyroidism
6.3.2.1. Imidazole
6.3.2.2. Propacil
6.4. Global Thyroid Gland Disorders Treatment Market Forecast, by Disorders
6.4.1. Hypothyroidism
6.4.1.1. Levothyroxine
6.4.1.2. Liothyronine
6.4.2. Hyperthyroidism
6.4.2.1. Imidazole
6.4.2.2. Propacil
6.5. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
6.5.1. Hypothyroidism
6.5.2. Hyperthyroidism
7. Global Thyroid Gland Disorders Treatment Market Analysis, by Region
7.1. Global Thyroid Gland Disorders Treatment Market Forecast, by Region, 2015–2025
7.1.1. North America
7.1.2. Europe
7.1.3. Asia Pacific
7.1.4. Latin America
7.1.5. Middle East & Africa
7.2. Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Region
7.3. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Region
8. North America Thyroid Gland Disorders Treatment Market Analysis
8.1. North America Thyroid Gland Disorders Treatment Market Key Findings
8.2. North America Thyroid Gland Disorders Treatment Market Overview
8.3. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
8.3.1. Hypothyroidism
8.3.1.1. Levothyroxine
8.3.1.2. Liothyronine
8.3.2. Hyperthyroidism
8.3.2.1. Imidazole
8.3.2.2. Propacil
8.4. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
8.4.1. Hypothyroidism
8.4.2. Hyperthyroidism
8.5. North America Thyroid Gland Disorders Treatment Market Forecast, by Country
8.5.1. U.S.
8.5.2. Canada
8.6. North America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
8.6.1. Hypothyroidism
8.6.2. Hyperthyroidism
9. Europe Thyroid Gland Disorders Treatment Market Analysis
9.1. Europe Thyroid Gland Disorders Treatment Market Key Findings
9.2. Europe Thyroid Gland Disorders Treatment Market Overview
9.3. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
9.3.1. Hypothyroidism
9.3.1.1. Levothyroxine
9.3.1.2. Liothyronine
9.3.2. Hyperthyroidism
9.3.2.1. Imidazole
9.3.2.2. Propacil
9.4. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
9.4.1. Hypothyroidism
9.4.2. Hyperthyroidism
9.5. Europe Thyroid Gland Disorders Treatment Market Forecast, by Country
9.5.1. Germany
9.5.2. U.K.
9.5.3. France
9.5.4. Italy
9.5.5. Spain
9.5.6. Rest of Europe
9.6. Europe Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
9.6.1. Hypothyroidism
9.6.2. Hyperthyroidism
10. Asia Pacific Thyroid Gland Disorders Treatment Market Analysis
10.1. Asia Pacific Thyroid Gland Disorders Treatment Market Key Findings
10.2. Asia Pacific Thyroid Gland Disorders Treatment Market Overview
10.3. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
10.3.1. Hypothyroidism
10.3.1.1. Levothyroxine
10.3.1.2. Liothyronine
10.3.2. Hyperthyroidism
10.3.2.1. Imidazole
10.3.2.2. Propacil
10.4. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
10.4.1. Hypothyroidism
10.4.2. Hyperthyroidism
10.5. Asia Pacific Thyroid Gland Disorders Treatment Market Forecast, by Country
10.5.1. China
10.5.2. India
10.5.3. Japan
10.5.4. Australia & New Zealand
10.5.5. Rest of Asia Pacific
10.6. Asia Pacific Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
10.6.1. Hypothyroidism
10.6.2. Hyperthyroidism
11. Latin America Thyroid Gland Disorders Treatment Market Analysis
11.1. Latin America Thyroid Gland Disorders Treatment Market Key Findings
11.2. Latin America Thyroid Gland Disorders Treatment Market Overview
11.3. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
11.3.1. Hypothyroidism
11.3.1.1. Levothyroxine
11.3.1.2. Liothyronine
11.3.2. Hyperthyroidism
11.3.2.1. Imidazole
11.3.2.2. Propacil
11.4. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
11.4.1. Hypothyroidism
11.4.2. Hyperthyroidism
11.5. Latin America Thyroid Gland Disorders Treatment Market Forecast, by Country
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Rest of Latin America
11.6. Latin America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
11.6.1. Hypothyroidism
11.6.2. Hyperthyroidism
12. Middle East & Africa Thyroid Gland Disorders Treatment Market Analysis
12.1. Middle East & Africa Thyroid Gland Disorders Treatment Market Key Findings
12.2. Middle East & Africa Thyroid Gland Disorders Treatment Market Overview
12.3. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
12.3.1. Hypothyroidism
12.3.1.1. Levothyroxine
12.3.1.2. Liothyronine
12.3.2. Hyperthyroidism
12.3.2.1. Imidazole
12.3.2.2. Propacil
12.4. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
12.4.1. Hypothyroidism
12.4.2. Hyperthyroidism
12.5. Middle East & Africa Thyroid Gland Disorders Treatment Market Forecast, by Country
12.5.1. GCC Countries
12.5.2. South Africa
12.5.3. Israel
12.5.4. Rest of Middle East & Africa
12.6. Middle East & Africa Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
12.6.1. Hypothyroidism
12.6.2. Hyperthyroidism
13. Competition Landscape
13.1. Global Thyroid Gland Disorders Treatment Market Share Analysis, by Company (2016)
13.2. Company Profiles
13.2.1. Merck KGaA
13.2.1.1. Overview (HQ, Employee Strength, Business Segments)
13.2.1.2. Financials
13.2.1.3. Recent Developments
13.2.1.4. Strategy
13.2.2. Pfizer, Inc.
13.2.2.1. Overview (HQ, Employee Strength, Business Segments)
13.2.2.2. Financials
13.2.2.3. Recent Developments
13.2.2.4. Strategy
13.2.3. Takeda Pharmaceutical Company Limited
13.2.3.1. Overview (HQ, Employee Strength, Business Segments)
13.2.3.2. Financials
13.2.3.3. Recent Developments
13.2.3.4. Strategy
13.2.4. ALLERGAN
13.2.4.1. Overview (HQ, Employee Strength, Business Segments)
13.2.4.2. Financials
13.2.4.3. Recent Developments
13.2.4.4. Strategy
13.2.5. Sanofi S.A.
13.2.5.1. Overview (HQ, Employee Strength, Business Segments)
13.2.5.2. Financials
13.2.5.3. Recent Developments
13.2.5.4. Strategy
13.2.6. AbbVie Inc.
13.2.6.1. Overview (HQ, Employee Strength, Business Segments)
13.2.6.2. Financials
13.2.6.3. Recent Developments
13.2.6.4. Strategy
13.2.7. Lannett Company, Inc.
13.2.7.1. Overview (HQ, Employee Strength, Business Segments)
13.2.7.2. Financials
13.2.7.3. Recent Developments
13.2.7.4. Strategy
13.2.8. Aspen
13.2.8.1. Overview (HQ, Employee Strength, Business Segments)
13.2.8.2. Financials
13.2.8.3. Recent Developments
13.2.8.4. Strategy
13.2.9. Novartis AG
13.2.9.1. Overview (HQ, Employee Strength, Business Segments)
13.2.9.2. Financials
13.2.9.3. Recent Developments
13.2.9.4. Strategy
13.2.10. Mylan N.V.
13.2.10.1. Overview (HQ, Employee Strength, Business Segments)
13.2.10.2. Financials
13.2.10.3. Recent Developments
13.2.10.4. Strategy
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers